Spots Global Cancer Trial Database for lung squamous cell carcinoma
Every month we try and update this database with for lung squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma | NCT02088515 | Squamous Cell C... | Nedaplatin Cisplatin Docetaxel | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma | NCT05024266 | Lung Squamous C... Neoadjuvant The... Immunotherapy | Tislelizumab | 18 Years - 75 Years | First Affiliated Hospital of Zhejiang University | |
| To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation | NCT04132102 | Lung Squamous C... | Afatinib | 18 Years - | Shanghai Chest Hospital | |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | NCT06255197 | Lung Cancer Lung Adenocarci... Lung Squamous C... Non Small Cell ... Small-cell Lung... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | ||
| Identify Prognostic Biomarkers of Lung Cancer | NCT05010330 | Lung Cancer Lung Adenocarci... Lung Squamous C... Non Small Cell ... | 18 Years - 80 Years | RenJi Hospital | ||
| A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | NCT05782764 | Lung Squamous C... | To explore the ... | 18 Years - 78 Years | Xuzhou Medical University | |
| Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | NCT04152018 | Squamous Cell C... Renal Cell Carc... Ovarian Cancer Gastric Cancer Esophageal Canc... Lung Squamous C... Pancreatic Canc... Bile Duct Cance... Endometrial Can... Melanoma Cancer Urothelial Canc... | PF-06940434 PF-06801591 | 18 Years - | Pfizer | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT00334815 | Lung Adenocarci... Lung Adenosquam... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage IIIA Lung... Stage IIIB Lung... | Bevacizumab Cisplatin Docetaxel Etoposide Filgrastim Pegfilgrastim Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma | NCT02088515 | Squamous Cell C... | Nedaplatin Cisplatin Docetaxel | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT01386385 | Lung Adenocarci... Lung Adenocarci... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... | 3-Dimensional C... Carboplatin Laboratory Biom... Paclitaxel Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Oral Rigosertib for Squamous Cell Carcinoma | NCT01807546 | Head and Neck S... Anal Squamous C... Lung Squamous C... Cervical Squamo... Esophageal Squa... Skin Squamous C... Penile Squamous... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | NCT05778253 | Lung Squamous C... | WES and ctDNA d... | 18 Years - 75 Years | Second Xiangya Hospital of Central South University | |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04267913 | Lung Squamous C... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Dexamethasone Docetaxel Ramucirumab Sapanisertib | - | SWOG Cancer Research Network | |
| Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | NCT06436040 | Tumor Microenvi... Lung Squamous C... Neoadjuvant Che... | Pathological re... | 40 Years - 80 Years | Tang-Du Hospital | |
| Apatinib for Advanced Lung Squmamous Carcinoma | NCT03725423 | Lung Squamous C... | Apatinib | 18 Years - | Xuzhou Central Hospital | |
| Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | NCT04152018 | Squamous Cell C... Renal Cell Carc... Ovarian Cancer Gastric Cancer Esophageal Canc... Lung Squamous C... Pancreatic Canc... Bile Duct Cance... Endometrial Can... Melanoma Cancer Urothelial Canc... | PF-06940434 PF-06801591 | 18 Years - | Pfizer | |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04267913 | Lung Squamous C... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Dexamethasone Docetaxel Ramucirumab Sapanisertib | - | SWOG Cancer Research Network | |
| Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | NCT02876978 | Lung Squamous C... | CAR-GPC3 T Cell... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | CARsgen Therapeutics Co., Ltd. | |
| Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer | NCT06121505 | Advanced Lung S... | low-dose radiat... chemotherapy Sintilimab | 18 Years - 75 Years | Sichuan University | |
| A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | NCT05782764 | Lung Squamous C... | To explore the ... | 18 Years - 78 Years | Xuzhou Medical University | |
| Oral Rigosertib for Squamous Cell Carcinoma | NCT01807546 | Head and Neck S... Anal Squamous C... Lung Squamous C... Cervical Squamo... Esophageal Squa... Skin Squamous C... Penile Squamous... | rigosertib | 18 Years - | Traws Pharma, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
